Financial PerformanceArrowhead is well-capitalized with $1.1B in cash, funded into 2028, and started to pay down the $400mm term loan with cash inflows from the collaboration.
Product LaunchThe upcoming launch of plozasiran is expected to pave the way for entry into the larger SHTG market, which has significant potential sales.
Strategic PartnershipsArrowhead reported significant revenues from its blockbuster licensing agreement with Sarepta.